Although treatment of bacterial sepsis with TLR4 antagonists may be limited to selected patients, there is a large potential of development for TLR4-oriented therapeutics to target sterile or microbially-induced inflammation. Here, TLR4 is linked to bacterial infectious disease with sepsis.